SIOPEN Clinical trials
A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta Antibody in children with relapsed/refractory Neuroblastoma. (The MINIVAN trial)
This is a phase I trial investigating combining 131-I mIBG therapy, anti-PD-1 antibody (Nivolumab) and anti-GD2 antibody (dinutuximab beta) in children with relapsed or refractory neuroblastoma.
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma (RIST-rNB-2011)
This study aims to improve the outcome of patients with relapsed or refractory neuroblastoma.
Prospective multicentre clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR)
This study aims to improve the outcome of patients with low and intermediate risk neuroblastoma. The study is evaluating the use RNA expression array based treatment stratification algorithm.
A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma (LuDO-N Trial)
The prognosis for children with relapsed or refractory high-risk neuroblastoma is dismal with very few survivors. As neuroblastoma is known to be a relatively radiosensitive tumor, targeted intravenous radiotherapy is an attractive treatment option and 131I-mIBG treatment has been used in a relapse setting, since the 1980’s.